Pharmaceutical
Health
Technology

Adamas Pharmaceuticals

$5.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-3.86%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADMS and other stocks, options, ETFs, and crypto commission-free!

About

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. Read More GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Employees
159
Headquarters
Emeryville, California
Founded
2000
Market Cap
157.69M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
571.67K
High Today
$5.98
Low Today
$5.67
Open Price
$5.90
Volume
140.00K
52 Week High
$31.94
52 Week Low
$5.36

Collections

Pharmaceutical
Health
Technology
Therapy
2014 IPO

Earnings

-$1.41
-$1.27
-$1.12
-$0.98
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.15 per share
Actual
-$1.08 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.